Innate Pharma S.A.
IPHA
$1.36
-$0.06-4.23%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.20M | -16.27M | -12.11M | -11.23M | -13.17M |
| Total Depreciation and Amortization | 394.00K | 395.70K | 401.20K | 372.00K | 454.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.18M | 1.18M | 2.07M | 1.92M | 723.80K |
| Change in Net Operating Assets | 2.06M | 2.07M | -8.04M | -7.46M | 6.70M |
| Cash from Operations | -12.57M | -12.62M | -17.68M | -16.40M | -5.29M |
| Capital Expenditure | -47.70K | -47.90K | -32.90K | -30.50K | -57.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 231.10K | 232.10K | 3.99M | 3.70M | 4.46M |
| Cash from Investing | 183.30K | 184.10K | 3.96M | 3.67M | 4.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.23M | -2.23M | -2.23M | -2.23M | -2.26M |
| Issuance of Common Stock | 24.50K | 24.50K | 7.47M | 7.47M | 1.42M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2.56M | -2.58M | 5.94M | 5.51M | -895.90K |
| Foreign Exchange rate Adjustments | 40.70K | 40.90K | 579.90K | 537.70K | -132.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.91M | -14.97M | -7.20M | -6.68M | -1.92M |